nonplus
发表于 2025-3-27 00:42:02
http://reply.papertrans.cn/39/3809/380877/380877_31.png
Anguish
发表于 2025-3-27 04:55:16
Precursors for upper gastrointestinal cancer: the need for screening,he utility of periodic surveillance for these conditions remains controversial. In this chapter, we describe the general conditions under which periodic screening constitutes optimal clinical practice. We then assess present knowledge about the relative benefits of screening patients with these specific precursor lesions.
Pudendal-Nerve
发表于 2025-3-27 06:48:43
http://reply.papertrans.cn/39/3809/380877/380877_33.png
Mortal
发表于 2025-3-27 11:21:37
http://reply.papertrans.cn/39/3809/380877/380877_34.png
laxative
发表于 2025-3-27 14:20:59
http://reply.papertrans.cn/39/3809/380877/380877_35.png
parsimony
发表于 2025-3-27 21:10:22
http://reply.papertrans.cn/39/3809/380877/380877_36.png
MOTIF
发表于 2025-3-28 00:54:26
Lymphomas of the gastrointestinal tract,), the gastrointestinal tract is the most common primary site of extranodal lymphoma . Non-Hodgkin’s lymphoma accounts for less than 20% of primary bowel malignancies and fewer than 5% of neoplasms of the stomach and colon . Roughly 1,300 new cases of primary gastrointestinal lymphoma are seen in the United States each year.
受辱
发表于 2025-3-28 03:48:32
Book 1987 papers on areas of high clinical relevance in malignant diseases of the gut. As in the first and second volumes of this series, authors have been selected for their expertise and national and international prominence in their fields. This volume is organized so that papers explaining basic science
共同给与
发表于 2025-3-28 08:19:58
Jean C. Tamraz,Youssef G. Comairn. Such alterations start a series of changes in the initiated cell that may ultimately culminate in the development of a neoplastic phenotype, i.e. uncontrolled growth and perhaps the ability to invade and metastasize. These changes are commonly accompanied by some degree of loss of cell differentiation.
Chronic
发表于 2025-3-28 11:36:37
https://doi.org/10.1007/978-3-030-86578-8these tumors, which may only become known when metastatic disease is manifested . Physicians who manage these patients require a full awareness of the biologic potential of these tumors as well as a proper balance of therapeutic restraint and aggressive medical and surgical management.